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T
he paper “Age dependency measured by calibrated auto-
mated thrombinography (CAT)” by Haidl et al. (1) is one
in a series of investigations from the Graz group that sig-
nificantly contributes to the understanding of paediatric haemos-
tasis. More or less as a by-product of these studies they now
found that adults of over 35 years of age have a significantly
higher thrombin generation potential (ETP) than those aged
from 18 – 35. The figure in this publication suggests an appar-
ently linear increase with age that is as high as ~30% between the
ages of 20 and 50. This is an important observation because it
shows that, also in a group of apparently healthy volunteers with-
out known prothrombotic traits, the age group that is more likely
to get thrombosis is also the one that generates more thrombin.
In a series of congenital conditions, such as antithrombin defi-
ciency (2), congenital hyperprothrombinaemia (G20210A mu-
tation) (3), and dysfunction of the protein C-system (unpublished
observation), it is evident that the genetic defect primarily causes
higher thrombin generation, and one concludes that higher throm-
bin generation leads to a higher risk of venous thrombosis. If we
observeAPC-resistance in the presence of the lupus anti(!)-coagu-
lant (4) or in women using oral contraceptives (5), it is not a long
shot to surmise that in these cases, as in congenital conditions,
higher thrombin generation is the cause of the thrombotic tenden-
cy. Taken together, the body of circumstantial evidence for high
thrombin generation potential being the cause of a prothrombotic
condition becomes rather impressive. It is reinforced again by the
inverse observation, i.e. the fact that all antithrombotic drugs de-
crease thrombin generation [see further (6)].
The observation by Haidl et al. carries the subject a step
further. It has been observed that thrombin generation is rather
variable in a normal population. Where the intraindividual vari-
ation of the ETP is ~5%, the interindividual variation is >15%
(7). This means that 99% of all normal individuals have a throm-
bin generating capacity of between 55 and 145 % of the mean. In
other words: some people in the normal population generate
twice as much thrombin as others. In congenital conditions such
as antithrombin deficiency or the prothrombin A20210G mu-
tation, such large variations can be attributed to one single cause.
Apparently, in the normal population they can also be caused by
a combination of circumstances. “Mr. Low” who, by chance, has
a low normal set of procoagulant factors and a high normal set of
anticoagulant factors may produce half as much thrombin when
his plasma is triggered compared to “Mrs. High”, a person with
high procoagulant and low anticoagulant factors. The question
now is whether, as a consequence, he has a much smaller risk of
developing thrombosis.
Now that automated calibrated measurement of thrombin
generation allows such variations to be measured, we feel that the
time is ripe for larger epidemiological studies relating the para-
meters of thrombin generation to thrombotic risk in those popu-
lations where no recognised risk factors can be found.
Before embarking upon such studies, epidemiologist may
well ask why thrombin generation might do better than the time
honoured clotting times, which have essentially failed as predic-
tors of thrombotic disease. The answer can be given on different
levels: i) Clotting times are insensitive to variations in clotting
function in the region of interest, i.e. in a large area around the
normal mean. If the thromboplastin time, as defined by Armand
Quick, is invariably 12 seconds in the normal, this is because it
does not distinguish between the clotting system of Mr. Low and
Mrs. High. This again is caused by the fact that the clotting time
already approaches its minimum when the concentration of pro-
thrombin (or of any other clotting factor) exceeds the ~25% level
(8). ii) At the moment that the clotting time is recorded there is
only very little thrombin formed. The large majority of all pro-
thrombin (> 98%) still has to be converted. So, not enough
thrombin is formed for the protein C system to start, and the plas-
ma antithrombins are not yet of significant influence. Contrary
to the clotting time, thrombin generation is very sensitive to vari-
ations of prothrombin and antithrombins around the normal
mean as well as to the activity of the APC system. iii) The con-
ditions of a thrombin generation experiment can be obtained re-
producibly at almost any concentration of tissue factor (TF). For
clotting times we have essentially the choice between an un-
physiologically large excess of TF, as in the thromboplastin time,
or an equally unphysiological absence of TF as in the activated
partial thromboplastin time (aPTT). Measuring clotting times at
lower TF concentrations is possible and has been practiced in the
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last century but has never become a routine measurement, pri-
marily because such clotting times are notoriously difficult to
standardise and validate. Thrombin generation curves can be ob-
tained reproducibly at any TF concentration, be it that in the pre-
sent technique, for technical reasons, a lag time (=clotting time)
of minimally 30 seconds is required, so that very highTF concen-
trations cannot be accommodated.
What concentration of TF must be considered “physiologi-
cal” is a question that is impossible to answer for the good reason
that, in vivo, TF is not present in free solution. It is incorporated
in a membrane that is very large compared to molecular dimen-
sions, and reaction velocities are determined by physical trans-
port rather than by chemical rate laws. The same holds true for
thrombomodulin (TM). TF and TM, representing the wound or
vessel wall in our experiments, are in practice simply added in
concentrations that make the thrombogram behave “physiologi-
cally”; i.e. in such amounts that it becomes sensitive to low con-
centrations of factorVIII and IX, to the defect in factorV Leiden,
to the effect of the pill etc. The crux of the matter lies in the fact
that with the calibrated automated thrombinography we have a
method at hand that is capable of giving reproducible results
under such circumstances. This, essentially, is also the under-
lying reason for Haidl et al. to surmise that the ETP “may be-
come a new tool better reflecting overall haemostasis than global
tests or specific factor analysis”(1).
There is one additional reason of interest in measuring the
thrombin forming capacity in the 55– 145% range. If, for a mo-
ment, we assume that epidemiology would show that the popu-
lation with an ETP between 100 and 145% has a higher incidence
of thrombosis than the 55–100% half, then the logical conclusion
must be that mild anticoagulation would have a preventive
effect. The literature abounds with antithrombotic drugs that do
not or hardly affect the clotting time, such as low doses of low
molecular weight heparin, fondoparinux, dermatan sulphate,
pentosan polysulfate and others. It is more than likely that
such drugs do influence the thrombin forming capacity to an ef-
ficient extent that, however, is not so large as to be measurable
with a clotting time. Large scale safe thrombosis prevention
might be obtained by some innocuous drug that does not dimin-
ish thrombin generation by more than 25%. Until now such ef-
fects were hard to measure. This posed problems for drug devel-
opment and control. With the CAT technique this becomes
readily possible.
Finally, the thrombosis mentioned above silently implied ve-
nous thrombosis. For arterial thrombosis the situation remains as
yet blurred – but as in venous thrombosis a central role of throm-
bin in the pathogenesis cannot be denied (9, 10), and ETP-lower-
ing therapies such as oral anticoagulation and heparin diminish
the rate of re-infarction (11–13). It may be that the links between
arterial thrombosis and thrombin generation become clearer
when epidemiological studies include thrombin generation in
platelet rich plasma. In this context it should not be overlooked
that “antiplatelet” agents invariably also diminish thrombin gen-
eration in platelet rich plasma (6, 14).
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